JP2018172391A5 - - Google Patents

Download PDF

Info

Publication number
JP2018172391A5
JP2018172391A5 JP2018106308A JP2018106308A JP2018172391A5 JP 2018172391 A5 JP2018172391 A5 JP 2018172391A5 JP 2018106308 A JP2018106308 A JP 2018106308A JP 2018106308 A JP2018106308 A JP 2018106308A JP 2018172391 A5 JP2018172391 A5 JP 2018172391A5
Authority
JP
Japan
Prior art keywords
factor
peptide
protein
fab
hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018106308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018172391A (ja
JP6800180B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018172391A publication Critical patent/JP2018172391A/ja
Publication of JP2018172391A5 publication Critical patent/JP2018172391A5/ja
Application granted granted Critical
Publication of JP6800180B2 publication Critical patent/JP6800180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018106308A 2013-08-30 2018-06-01 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法 Active JP6800180B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2013-0104112 2013-08-30
KR20130104112 2013-08-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016538860A Division JP6422977B2 (ja) 2013-08-30 2014-08-29 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法

Publications (3)

Publication Number Publication Date
JP2018172391A JP2018172391A (ja) 2018-11-08
JP2018172391A5 true JP2018172391A5 (enExample) 2019-02-14
JP6800180B2 JP6800180B2 (ja) 2020-12-16

Family

ID=52586989

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016538860A Active JP6422977B2 (ja) 2013-08-30 2014-08-29 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法
JP2018106308A Active JP6800180B2 (ja) 2013-08-30 2018-06-01 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016538860A Active JP6422977B2 (ja) 2013-08-30 2014-08-29 抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法

Country Status (16)

Country Link
US (2) US9879077B2 (enExample)
EP (2) EP3632930A1 (enExample)
JP (2) JP6422977B2 (enExample)
KR (2) KR101576561B1 (enExample)
CN (1) CN105899532B (enExample)
AU (1) AU2014312456B2 (enExample)
BR (1) BR112016004355A2 (enExample)
CA (1) CA2922618C (enExample)
DK (1) DK3039038T3 (enExample)
ES (1) ES2866848T3 (enExample)
MX (1) MX371328B (enExample)
PH (1) PH12016500403A1 (enExample)
PL (1) PL3039038T3 (enExample)
RU (1) RU2661087C2 (enExample)
UA (1) UA117493C2 (enExample)
WO (1) WO2015030539A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
CA3102036A1 (en) * 2018-06-18 2019-12-26 Anwita Biosciences, Inc. Cytokine fusion proteins and uses thereof
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
BR112022020256A2 (pt) 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
KR20220044057A (ko) * 2020-09-29 2022-04-06 주식회사 에이프릴바이오 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
CN116262786B (zh) * 2021-12-13 2026-05-15 南京融捷康生物科技有限公司 针对folr1的单域抗体及其衍生蛋白和应用
KR20250024825A (ko) * 2022-06-15 2025-02-19 유씨비 바이오파마 에스알엘 폴리스타틴-fc 융합 단백질
KR20240048577A (ko) * 2022-10-04 2024-04-16 주식회사 에이프릴바이오 난포자극 호르몬 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN117327194A (zh) * 2023-09-01 2024-01-02 中国农业科学院生物技术研究所 细胞因子和铁蛋白亚基的融合蛋白及其制备方法和应用
WO2025253161A1 (en) * 2024-06-05 2025-12-11 Aprilbio Co., Ltd. Methods for treating liver diseases using recombinant fusion proteins comprising interleukin-18-binding protein and antigen binding fragment to serum albumin
CN118393137B (zh) * 2024-07-01 2024-08-20 广东赛尔生物科技有限公司 一种肠道保护菌的检测试剂盒及其应用
WO2026055874A1 (en) * 2024-09-12 2026-03-19 Quaerite Biopharm Research (Beijing) Co., Ltd. Formulations containing human serum albumin and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CN101031588A (zh) * 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物，融合物和结合物
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
KR20070041781A (ko) * 2004-08-11 2007-04-19 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인 융합 단백질
CA2583137A1 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Therapeutic agents with decreased toxicity
CA2589802A1 (en) * 2004-12-02 2006-06-08 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
EP1860120B1 (en) * 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Method for improving antibody
WO2008151319A2 (en) * 2007-06-08 2008-12-11 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of ch1 domain
EP2535350B1 (en) * 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
JP5639039B2 (ja) * 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
CN102307897B (zh) * 2008-12-05 2016-01-20 葛兰素集团有限公司 选出蛋白酶抗性多肽的方法
WO2011015649A1 (en) * 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
KR20120092611A (ko) * 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
JP6411214B2 (ja) * 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片

Similar Documents

Publication Publication Date Title
RU2016105586A (ru) Гибридная конструкция, включающая антигенсвязывающий фрагмент, специфичный к сывороточному альбумину и эффекторный компонент, и способы ее получения
JP6689329B2 (ja) 免疫グロブリンＦｃ変異体
KR101200659B1 (ko) 세 말단 반응기를 갖는 비펩타이드성 중합체를 이용한 생리활성 폴리펩타이드 약물 결합체
AU2005311099B2 (en) Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
CA2512933A1 (en) A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
Kontermann Strategies for extended serum half-life of protein therapeutics
ES2623925T3 (es) Proteínas de fusión de inmunoglobulina
JP2020023520A (ja) コイルドコイルの免疫グロブリン融合タンパク質およびその組成物
CN106661128A (zh) 构建氨基末端免疫球蛋白融合蛋白的方法及其组合物
JP2007537992A5 (enExample)
JP2007536211A5 (enExample)
US20260035426A1 (en) Il-15 prodrug and uses thereof
JP2021525807A5 (enExample)
TH2201000302A (th) วิธีการใหม่สำหรับการเตรียมคอนจูเกตยาที่ออกฤทธิ์ยาวนานโดยการเตรียมตัวกลาง